Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay808 in mild to moderate atopic dermatitis (phase II)
CTR20200389Phase 2Completed
- Sponsor
- Tianjin Hemay Oncology Pharmaceutical
- Start
- Mar 2020
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of hemay808 in atopic dermatitis (AD), sponsored by Tianjin Hemay Oncology Pharmaceutical. Started Mar 2020; status: completed.
02
Drugs
hemay808
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20200389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200389.